

**BAKER BOTTS LLP**Please type a plus sign (+) inside this box → **+****TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/795,927
	Filing Date	March 8, 2004
	First Named Inventor	Fisher
	Group Art Unit	1614
	Examiner Name	To be assigned
Total Number of Pages in This Submission	Attorney Docket Number	A34694-A-PCT-USA-A

ENCLOSURES (check all that apply)


<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1) IDS-Volumes 1 to 4 of 4, 2) PTO Form 1449 (17 pages), 3) Request for a corrected filing receipt (2 pages), 4) Return postcard.
Remarks <input type="checkbox"/>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	BakerBotts LLP 30 Rockefeller Plaza New York, NY 10112	
Signature		Att Name: Lisa B. Kole PTO Reg: 35,225
Date	November 16, 2004	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this date: November 16, 2004		
Typed or printed name	Lisa B. Kole	
Signature		Date November 16, 2004



NOV 22 2004

BAKER BOTTS LLP

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 0

Complete if Known

Application Number	10/795,927
Filing Date	March 8, 2004
First Named Inventor	Fisher
Examiner Name	To be assigned
Art Unit	1614
Attorney Docket No.	A34694-A-PCT-USA-A

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☐ Deposit Account:Deposit
Account
Number
Deposit
Account
Name

02-4377

Baker Botts LLP

The Commissioner is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee required under 37CFR 1.16 and 1.17☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	
SUBTOTAL (1)					(\$ 0

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims		=	0	X		=	0
Independent Claims		=	0	X		=	0
Multiple Dependent		=		X		=	

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ 0

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,300	2453	650	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	630	2503	315	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 0

SUBMITTED BY

Name (Print/Type)

Lisa B. Kole

Registration No.
(Attorney/Agent)

35,225

(Complete if applicable)

Telephone 212 408 2500

Signature

Date November 16 2004

BAKER BOTTS LLP

Attorney Docket Number: A34694-A-PCT-USA-A

Title: ANTI-TUMOR EFFECTS OF PROSTATE CARCINOMA TUMOR ANTIGEN-1



Use Space Below for Additional Information:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant : Fisher et al.

Application No.: 10/795,927 Authorized Officer: TBA

Filed : March 8, 2004 Group Art Unit: 1614

For : ANTI-TUMOR EFFECTS OF PROSTATE CARCINOMA
TUMOR ANTIGEN-I

INFORMATION
DISCLOSURE
STATEMENT

I hereby certify that this paper is being deposited with the United States
Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, Washington, D.C. 20231

November 16 2004

Date of Deposit

Lisa B. Kole, M.D., Ph.D.

Attorney Name

A handwritten signature in black ink, appearing to read "Lisa B. Kole", written over a horizontal line.

Signature

35,225

PTO Registration No.

November 16 2004

Date of Signature

Commissioner for Patents

Washington, D.C. 20231

Sir:

Pursuant to the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants respectfully
request that the references relating to the above-mentioned application listed herein be
made of record in the U.S. Patent and Trademark Office. The referenced citations are
listed in the accompanying PTO Form 1449 and copies of the references are enclosed.

1. United States Patent No. 6,255,071 by Beach et al., issued July 3, 2001. Mammalian viral vectors and their uses.
2. United States Patent No. 6,255,049 by Fisher, issued July 3, 2001. Detection of metastatic cancer cells using PCTA-1.
3. United States Patent No. 6,184,032 by Fisher, issued February 6, 2001. Identification of genes encoding cell surface antigens using CREF-Trans 6 cells.
4. Hotta, K., Funahashi, T., Matsukawa, Y., Takahashi, M., Nishizawa, H., Kishida, K., Matsuda, M., Kuriyama, H., Kihara, S., Nakamura, T., *et al.* (2001). Galectin-12, an Adipose-expressed Galectin-like Molecule Possessing Apoptosis-inducing Activity. *J Biol Chem* 276, 34089-34097.
5. Peng, X. Y., Won, J. H., Rutherford, T., Fujii, T., Zelterman, D., Pizzorno, G., Sapi, E., Leavitt, J., Kacinski, B., Crystal, R., *et al.* (2001). The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. *Cancer Res* 61, 4405-4413.
6. Perrais, M., Pigny, P., Ducourouble, M. P., Petitprez, D., Porchet, N., Aubert, J. P., and Van Seuningen, I. (2001). Characterization of human mucin gene MUC4 promoter: importance of growth factors and proinflammatory cytokines for its regulation in pancreatic cancer cells. *J Biol Chem* 276, 30923-30933.
7. Tanaka, M., Inase, N., Miyake, S., and Yoshizawa, Y. (2001). Neuron specific enolase promoter for suicide gene therapy in small cell lung carcinoma. *Anticancer Res* 21, 291-294.
8. Xie, X., Zhao, X., Liu, Y., Young, C. Y., Tindall, D. J., Slawin, K. M., and Spencer, D. M. (2001). Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter. *Hum Gene Ther* 12, 549-561.
9. Adachi, Y., Reynolds, P. N., Yamamoto, M., Grizzle, W. E., Overturf, K., Matsubara, S., Muramatsu, T., and Curiel, D. T. (2000). Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors. *Cancer Res* 60, 4305-4310.
10. United States Patent No. 6,025,192 by Beach et al., issued February 15, 2000. Modified retroviral vectors.
11. Curran, M. A., Kaiser, S. M., Achacoso, P. L., and Nolan, G. P. (2000). Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. *Mol Ther* 1, 31-38.
12. United States Patent No. 6,159,751 by Fisher, issued December 12, 2000. Development of DNA probes and immunological reagents of human tumor associated antigens.

13. Gopalkrishnan, R. V., Roberts, T., Tuli, S., Kang, D., Christiansen, K. A., and Fisher, P. B. (2000). Molecular characterization of prostate carcinoma tumor antigen-1, PCTA-1, a human galectin-8 related gene. *Oncogene 19*, 4405-4416.
14. Inase, N., Horita, K., Tanaka, M., Miyake, S., Ichioka, M., and Yoshizawa, Y. (2000). Use of gastrin-releasing peptide promoter for specific expression of thymidine kinase gene in small-cell lung carcinoma cells. *Int J Cancer 85*, 716-719.
15. O'Keefe, D. S., Uchida, A., Bacich, D. J., Watt, F. B., Martorana, A., Molloy, P. L., and Heston, W. D. (2000). Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. *Prostate 45*, 149-157.
16. Van Seuning, et al. (2000). Homo sapiens mucin (MUC4) gene, promoter sequence and partial cds. GenBank Accession No. AF241535.
17. Bassen, R., Brichory, F., Caulet-Maugendre, S., Bidon, N., Delaval, P., Desrues, B., and Dazord, L. (1999). Expression of Po66-CBP, a type-8 galectin, in different healthy, tumoral and peritumoral tissues. *Anticancer Res 19*, 5429-5433.
18. Case, S. S., Price, M. A., Jordan, C. T., Yu, X. J., Wang, L., Bauer, G., Haas, D. L., Xu, D., Stripecke, R., Naldini, L., et al. (1999). Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. *Proc Natl Acad Sci U S A 96*, 2988-2993.
19. Connelly, S. (1999). Adenoviral vectors for liver-directed gene therapy. *Curr Opin Mol Ther 1*, 565-572.
20. Cooper, D. N., and Barondes, S. H. (1999). God must love galectins; he made so many of them. *Glycobiology 9*, 979-984.
21. Ellerhorst, J., Nguyen, T., Cooper, D. N., Lotan, D., and Lotan, R. (1999). Differential expression of endogenous galectin-1 and galectin-3 in human prostate cancer cell lines and effects of overexpressing galectin-1 on cell phenotype. *Int J Oncol 14*, 217-224.
22. WIPO, International Patent Application WO 99/49898 by Fisher. Publication date: July, 10 1999. Progression Elevated Gene-3 and uses thereof.
23. Gopalkrishnan, R. V., Christiansen, K. A., Goldstein, N. I., DePinho, R. A., and Fisher, P. B. (1999). Use of the human EF-1alpha promoter for expression can significantly increase success in establishing stable cell lines with consistent expression: a study using the tetracycline-inducible system in human cancer cells. *Nucleic Acids Res 27*, 4775-4782.

24. Greenhalgh, C. J., Beckham, S. A., and Newton, S. E. (1999). Galectins from sheep gastrointestinal nematode parasites are highly conserved. *Mol Biochem Parasitol* 98, 285-289.
25. Hsu, D. K., Dowling, C. A., Jeng, K. C., Chen, J. T., Yang, R. Y., and Liu, F. T. (1999). Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. *Int J Cancer* 81, 519-526.
26. Katabi, M. M., Chan, H. L., Karp, S. E., and Batist, G. (1999). Hexokinase type II: a novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells. *Hum Gene Ther* 10, 155-164.
27. Lu, Y., and Lotan, R. (1999). Transcriptional regulation by butyrate of mouse galectin-1 gene in embryonal carcinoma cells. *Biochim Biophys Acta* 1444, 85-91.
28. Maldonado, C. A., Castagna, L. F., Rabinovich, G. A., and Landa, C. A. (1999). Immunocytochemical Study of the Distribution of a 16-kDa Galectin in the Chicken Retina. *Invest Ophthalmol Vis Sci* 40, 2971-2977.
29. Pan, C. X., and Koeneman, K. S. (1999). A novel tumor-specific gene therapy for bladder cancer. *Med Hypotheses* 53, 130-135.
30. Polo, J. M., Belli, B. A., Driver, D. A., Frolov, I., Sherrill, S., Hariharan, M. J., Townsend, K., Perri, S., Mento, S. J., Jolly, D. J., *et al.* (1999). Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. *Proc Natl Acad Sci U S A* 96, 4598-4603.
31. Puch, S., and Bhavanandan, V. P. (1999). Endogenous carbohydrate-binding proteins of rabbit and human bladder. *Urology* 53, 848-852.
32. Remmelink, M., Darro, F., Decaestecker, C., De Decker, R., Bovin, N. V., Gebhart, M., Kaltner, H., Gabius, H. J., Kiss, R., Salmon, I., and Danguy, A. (1999). In vitro influence of lectins and neoglycoconjugates on the growth of three human sarcoma cell lines. *J Cancer Res Clin Oncol* 125, 275-285.
33. Stackhouse, M. A., Buchsbaum, D. J., Kancharla, S. R., Grizzle, W. E., Grimes, C., Laffoon, K., Pederson, L. C., and Curiel, D. T. (1999). Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors. *Cancer Gene Ther* 6, 209-219.
34. Willis, A. E. (1999). Translational control of growth factor and proto-oncogene expression. *Int J Biochem Cell Biol* 31, 73-86.
35. Zhang, W. W. (1999). Development and application of adenoviral vectors for gene therapy of cancer. *Cancer Gene Ther* 6, 113-138.

36. Berthon, P., Valeri, A., Cohen-Akenine, A., Drelon, E., Paiss, T., Wohr, G., Latil, A., Millasseau, P., Mellah, I., Cohen, N., *et al.* (1998). Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. *Am J Hum Genet* 62, 1416-1424.
37. Blaser, C., Kaufmann, M., Muller, C., Zimmermann, C., Wells, V., Mallucci, L., and Pircher, H. (1998). Beta-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. *Eur J Immunol* 28, 2311-2319.
38. Brichory, et al. (1998). Homo sapiens Po66 carbohydrate binding protein mRNA, complete cds. GenBank Accession No. AF074000.
39. Brichory, et al. (1998). Homo sapiens Po66 carbohydrate binding protein 1 mRNA, complete cds. GenBank Accession No. AF074001.
40. Brichory, et al. (1998). Homo sapiens Po66 carbohydrate binding protein 2 mRNA, complete cds. GenBank Accession No. AF074002.
41. Cortegano, I., del Pozo, V., Cardaba, B., de Andres, B., Gallardo, S., del Amo, A., Arrieta, I., Jurado, A., Palomino, P., Liu, F. T., and Lahoz, C. (1998). Galectin-3 down-regulates IL-5 gene expression on different cell types. *J Immunol* 161, 385-389.
42. United States Patent No. 5,851,764 by Fisher et al., issued December 22, 1998. Human prostate tumor inducing gene-1 and uses thereof.
43. Gitt, M. A., Colnot, C., Poirier, F., Nani, K. J., Barondes, S. H., and Leffler, H. (1998). Galectin-4 and galectin-6 are two closely related lectins expressed in mouse gastrointestinal tract. *J Biol Chem* 273, 2954-2960.
44. Gitt, M. A., Xia, Y. R., Atchison, R. E., Lusi, A. J., Barondes, S. H., and Leffler, H. (1998). Sequence, structure, and chromosomal mapping of the mouse Lgals6 gene, encoding galectin-6. *J Biol Chem* 273, 2961-2970.
45. Iglesias, M. M., Rabinovich, G. A., Ambrosio, A. L., Castagna, L. F., Sotomayor, C. E., and Wolfenstein-Todel, C. (1998). Purification of galectin-3 from ovine placenta: developmentally regulated expression and immunological relevance. *Glycobiology* 8, 59-65.
46. Kaltner, H., and Stierstorfer, B. (1998). Animal lectins as cell adhesion molecules. *Acta Anat (Basel)* 161, 162-179.
47. Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML, Matusik RJ. (1998). Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. *Lab Invest.* 1998 78(3):319-333.

48. Lu, Y., Amos, B., Cruise, E., Lotan, D., and Lotan, R. (1998). A parallel association between differentiation and induction of galectin-1, and inhibition of galectin-3 by retinoic acid in mouse embryonal carcinoma F9 cells. *Biol Chem* 379, 1323-1331.
49. Olsen, J. C. (1998). Gene transfer vectors derived from equine infectious anemia virus. *Gene Ther* 5, 1481-1487.
50. Sarafian, V., Jadot, M., Foidart, J. M., Letesson, J. J., Van den Brule, F., Castronovo, V., Wattiaux, R., and Coninck, S. W. (1998). Expression of Lamp-1 and Lamp-2 and their interactions with galectin-3 in human tumor cells. *Int J Cancer* 75, 105-111.
51. Su, Z. Z., Madireddi, M. T., Lin, J. J., Young, C. S., Kitada, S., Reed, J. C., Goldstein, N. I., and Fisher, P. B. (1998). The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. *Proc Natl Acad Sci U S A* 95, 14400-14405.
52. Vyakarnam, A., Lenneman, A. J., Lakkides, K. M., Patterson, R. J., and Wang, J. L. (1998). A comparative nuclear localization study of galectin-1 with other splicing components. *Exp Cell Res* 242, 419-428.
53. Akahani, S., Nangia-Makker, P., Inohara, H., Kim, H. R., and Raz, A. (1997). Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. *Cancer Res* 57, 5272-5276.
54. Arata, Y., Hirabayashi, J., and Kasai, K. (1997). The two lectin domains of the tandem-repeat 32-kDa galectin of the nematode *Caenorhabditis elegans* have different binding properties. Studies with recombinant protein. *J Biochem (Tokyo)* 121, 1002-1009.
55. Bresalier, R. S., Yan, P. S., Byrd, J. C., Lotan, R., and Raz, A. (1997). Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. *Cancer* 80, 776-787.
56. Chadli, A., LeCaer, J. P., Bladier, D., Joubert-Caron, R., and Caron, M. (1997). Purification and characterization of a human brain galectin-1 ligand. *J Neurochem* 68, 1640-1647.
57. Cooper, D. N., Boulianne, R. P., Charlton, S., Farrell, E. M., Sucher, A., and Lu, B. C. (1997). Fungal galectins, sequence and specificity of two isolectins from *Coprinus cinereus*. *J Biol Chem* 272, 1514-1521.
58. Hughes, R. C. (1997). The galectin family of mammalian carbohydrate-binding molecules. *Biochem Soc Trans* 25, 1194-1198.

59. Lutomski, D., Fouillit, M., Bourin, P., Mellottee, D., Denize, N., Pontet, M., Bladier, D., Caron, M., and Joubert-Caron, R. (1997). Externalization and binding of galectin-1 on cell surface of K562 cells upon erythroid differentiation. *Glycobiology* 7, 1193-1199.
60. Maquoi, E., van den Brule, F. A., Castronovo, V., and Foidart, J. M. (1997). Changes in the distribution pattern of galectin-1 and galectin-3 in human placenta correlates with the differentiation pathways of trophoblasts. *Placenta* 18, 433-439.
61. Mehul, B., and Hughes, R. C. (1997). Plasma membrane targeting, vesicular budding and release of galectin 3 from the cytoplasm of mammalian cells during secretion. *J Cell Sci* 110 (Pt 10), 1169-1178.
62. Takakuwa, K., Fujita, K., Kikuchi, A., Sugaya, S., Yahata, T., Aida, H., Kurabayashi, T., Hasegawa, I., and Tanaka, K. (1997). Direct intratumoral gene transfer of the herpes simplex virus thymidine kinase gene with DNA-liposome complexes: growth inhibition of tumors and lack of localization in normal tissues. *Jpn J Cancer Res* 88, 166-175.
63. Vyakarnam, A., Dagher, S. F., Wang, J. L., and Patterson, R. J. (1997). Evidence for a role for galectin-1 in pre-mRNA splicing. *Mol Cell Biol* 17, 4730-4737.
64. Wada, J., and Kanwar, Y. S. (1997). Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. *J Biol Chem* 272, 6078-6086.
65. Boyce, F. M., and Bucher, N. L. (1996). Baculovirus-mediated gene transfer into mammalian cells. *Proc Natl Acad Sci U S A* 93, 2348-2352.
66. Bresalier, R. S., Byrd, J. C., Wang, L., and Raz, A. (1996). Colon cancer mucin: a new ligand for the beta-galactoside-binding protein galectin-3. *Cancer Res* 56, 4354-4357.
67. Chammas, R., Jasiulionis, M. G., Ventura, A. M., Travassos, L. R., and Brentani, R. R. (1996). Laminin-binding proteins in EJ-ras-transformed fibroblasts. *Braz J Med Biol Res* 29, 1141-1149.
68. Colnot, C., Ripoche, M. A., Scaerou, F., Foulis, D., and Poirier, F. (1996). Galectins in mouse embryogenesis. *Biochem Soc Trans* 24, 141-146.
69. WIPO, International Patent Application WO 96/21671 by Fisher et al., Publication date: July 18, 1996. International Application No. PCT/US96/00307. Development of DNA probes and immunological reagents specific for cell surface-expressed molecules and transformation-associated genes.
70. Gillenwater, A., Xu, X. C., el-Naggar, A. K., Clayman, G. L., and Lotan, R. (1996). Expression of galectins in head and neck squamous cell carcinoma. *Head Neck* 18, 422-432.

71. Gingrich, J. R., Barrios, R. J., Morton, R. A., Boyce, B. F., DeMayo, F. J., Finegold, M. J., Angelopoulou, R., Rosen, J. M., and Greenberg, N. M. (1996). Metastatic prostate cancer in a transgenic mouse. *Cancer Res* 56, 4096-4102.
72. Gopalkrishnan, R. V., Dolle, P., Mattei, M. G., La Thangue, N. B., and Kedinger, C. (1996). Genomic structure and developmental expression of the mouse cell cycle regulatory transcription factor DP1. *Oncogene* 13, 2671-2680.
73. Hadj Sahraoui, Y., Sève, A.-P., Doyennette-Moyne, M.-A., Saffar, L., Felin, M., Aubery, M., Gattegno, L., and Hubert, J. (1996). Nuclear and cytoplasmic expressions of the carbohydrate-binding protein CBP70 in tumoral or healthy cells of the macrophagic lineage. *J Cell Biochem* 62, 529-542.
74. Hebert, E., Roche, A. C., Nachtigal, M., and Monsigny, M. (1996). Transformation but not ras-transfection increases the expression of galectin-3 in human HOS cells. *C R Acad Sci III* 319, 871-877.
75. Jiang, H., Su, Z. Z., Lin, J. J., Goldstein, N. I., Young, C. S., and Fisher, P. B. (1996). The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. *Proc Natl Acad Sci U S A* 93, 9160-9165.
76. Kasai, K., and Hirabayashi, J. (1996). Galectins: a family of animal lectins that decipher glycodes. *J Biochem (Tokyo)* 119, 1-8.
77. Lan, K. H., Kanai, F., Shiratori, Y., Okabe, S., Yoshida, Y., Wakimoto, H., Hamada, H., Tanaka, T., Ohashi, M., and Omata, M. (1996). Tumor-specific gene expression in carcinoembryonic antigen--producing gastric cancer cells using adenovirus vectors. *Gastroenterology* 111, 1241-1251.
78. Strayer, D. S., and Milano, J. (1996). SV40 mediates stable gene transfer in vivo. *Gene Ther* 3, 581-587.
79. Su, Z. Z., Lin, J., Shen, R., Fisher, P. E., Goldstein, N. I., and Fisher, P. B. (1996). Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family. *Proc Natl Acad Sci U S A* 93, 7252-7257.
80. Su, Z. Z. et al. (1996). Human prostate carcinoma tumor antigen (pcta-1) mRNA, complete cds. GenBank Accession No L78132.
81. Wagner-Hulsmann, C., Bachinski, N., Diehl-Seifert, B., Blumbach, B., Steffen, R., Pancer, Z., and Muller, W. E. (1996). A galectin links the aggregation factor to cells in the sponge (*Geodia cydonium*) system. *Glycobiology* 6, 785-793.
82. Yang, R. Y., Hsu, D. K., and Liu, F. T. (1996). Expression of galectin-3 modulates T-cell growth and apoptosis. *Proc Natl Acad Sci U S A* 93, 6737-6742.

83. Cho, M., and Cummings, R. D. (1995a). Galectin-1, a beta-galactoside-binding lectin in Chinese hamster ovary cells. II. Localization and biosynthesis. *J Biol Chem* 270, 5207-5212.
84. Cho, M., and Cummings, R. D. (1995b). Galectin-1, a beta-galactoside-binding lectin in Chinese hamster ovary cells. I. Physical and chemical characterization. *J Biol Chem* 270, 5198-5206.
85. Dagher, S. F., Wang, J. L., and Patterson, R. J. (1995). Identification of galectin-3 as a factor in pre-mRNA splicing. *Proc Natl Acad Sci U S A* 92, 1213-1217.
86. Gitt, M. A., Wiser, M. F., Leffler, H., Herrmann, J., Xia, Y. R., Massa, S. M., Cooper, D. N., Lusic, A. J., and Barondes, S. H. (1995). Sequence and mapping of galectin-5, a beta-galactoside-binding lectin, found in rat erythrocytes. *J Biol Chem* 270, 5032-5038.
87. Greenberg, N. M., DeMayo, F., Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., Cunha, G. R., Donjacour, A. A., Matusik, R. J., and Rosen, J. M. (1995). Prostate cancer in a transgenic mouse. *Proc Natl Acad Sci U S A* 92, 3439-3443.
88. Hadari, Y. R., Paz, K., Dekel, R., Mestrovic, T., Accili, D., and Zick, Y. (1995). Galectin-8. A new rat lectin, related to galectin-4. *J Biol Chem* 270, 3447-3453.
89. Ido, A., Nakata, K., Kato, Y., Nakao, K., Murata, K., Fujita, M., Ishii, N., Tamaoki, T., Shiku, H., and Nagataki, S. (1995). Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. *Cancer Res* 55, 3105-3109.
90. Inohara, H., and Raz, A. (1995). Functional evidence that cell surface galectin-3 mediates homotypic cell adhesion. *Cancer Res* 55, 3267-3271.
91. Li, Y. S., Ramsay, D. A., Fan, Y. S., Armstrong, R. F., and Del Maestro, R. F. (1995). Cytogenetic evidence that a tumor suppressor gene in the long arm of chromosome 1 contributes to glioma growth. *Cancer Genet Cytogenet* 84, 46-50.
92. Perillo, N. L., Pace, K. E., Seilhamer, J. J., and Baum, L. G. (1995). Apoptosis of T cells mediated by galectin-1. *Nature* 378, 736-739.
93. Rini, J. M. (1995). X-ray crystal structures of animal lectins. *Curr Opin Struct Biol* 5, 617-621.
94. Schoeppner, H. L., Raz, A., Ho, S. B., and Bresalier, R. S. (1995). Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. *Cancer* 75, 2818-2826.

95. Barondes, S. H., Castronovo, V., Cooper, D. N., Cummings, R. D., Drickamer, K., Feizi, T., Gitt, M. A., Hirabayashi, J., Hughes, C., Kasai, K., and et al. (1994). Galectins: a family of animal beta-galactoside-binding lectins. *Cell* 76, 597-598.
96. Barondes, S. H., Cooper, D. N., Gitt, M. A., and Leffler, H. (1994). Galectins. Structure and function of a large family of animal lectins. *J Biol Chem* 269, 20807-20810.
97. Bett, A. J., Haddara, W., Prevec, L., and Graham, F. L. (1994). An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. *Proc Natl Acad Sci U S A* 91, 8802-8806.
98. Hayashi, Y., DePaoli, A. M., Burant, C. F., and Refetoff, S. (1994). Expression of a thyroid hormone-responsive recombinant gene introduced into adult mice livers by replication-defective adenovirus can be regulated by endogenous thyroid hormone receptor. *J Biol Chem* 269, 23872-23875.
99. Lotan, R., Belloni, P. N., Tressler, R. J., Lotan, D., Xu, X. C., and Nicolson, G. L. (1994). Expression of galectins on microvessel endothelial cells and their involvement in tumour cell adhesion. *Glycoconj J* 11, 462-468.
100. Murty, V. V., Li, R. G., Mathew, S., Reuter, V. E., Bronson, D. L., Bosl, G. J., and Chaganti, R. S. (1994). Replication error-type genetic instability at 1q42-43 in human male germ cell tumors. *Cancer Res* 54, 3983-3985.
101. Rossi, J. J. (1994). Practical ribozymes. Making ribozymes work in cells. *Curr Biol* 4, 469-471.
102. Shen, R., Su, Z. Z., Olsson, C. A., Goldstein, N. I., and Fisher, P. B. (1994). Surface-epitope masking: a strategy for the development of monoclonal antibodies specific for molecules expressed on the cell surface. *J Natl Cancer Inst* 86, 91-98.
103. Welch, D. R., Chen, P., Miele, M. E., McGary, C. T., Bower, J. M., Stanbridge, E. J., and Weissman, B. E. (1994). Microcell-mediated transfer of chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorigenicity. *Oncogene* 9, 255-262.
104. Li, Q., Kay, M. A., Finegold, M., Stratford-Perricaudet, L. D., and Woo, S. L. (1993). Assessment of recombinant adenoviral vectors for hepatic gene therapy. *Hum Gene Ther* 4, 403-409.
105. Mastrangeli, A., Danel, C., Rosenfeld, M. A., Stratford-Perricaudet, L., Perricaudet, M., Pavirani, A., Lecocq, J. P., and Crystal, R. G. (1993). Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer. *J Clin Invest* 91, 225-234.

106. Ragot, T., Vincent, N., Chafey, P., Vigne, E., Gilgenkrantz, H., Couton, D., Cartaud, J., Briand, P., Kaplan, J. C., Perricaudet, M., and et al. (1993). Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. *Nature* 361, 647-650.
107. United States Patent No. 5,093,246 by Cech et al., issued March 3, 1992. RNA ribozyme polymerases, dephosphorylases, restriction endoribo-nucleases and methods.
108. WIPO, International Patent Application WO 92/08131, by Fisher. Publication date: May 14, 1992. International Application No. PCT/US91/07912. Development of DNA probes and immunological reagents of human tumor associated antigens.
109. Jaffe, H. A., Danel, C., Longenecker, G., Metzger, M., Setoguchi, Y., Rosenfeld, M. A., Gant, T. W., Thorgeirsson, S. S., Stratford-Perricaudet, L. D., Perricaudet, M., and et al. (1992). Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. *Nat Genet* 1, 372-378.
110. Legendre, J. Y., and Szoka, F. C., Jr. (1992). Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: comparison with cationic liposomes. *Pharm Res* 9, 1235-1242.
111. Quantin, B., Perricaudet, L. D., Tajbakhsh, S., and Mandel, J. L. (1992). Adenovirus as an expression vector in muscle cells in vivo. *Proc Natl Acad Sci U S A* 89, 2581-2584.
112. Rosenfeld, M. A., Yoshimura, K., Trapnell, B. C., Yoneyama, K., Rosenthal, E. R., Dalemans, W., Fukayama, M., Bargon, J., Stier, L. E., Stratford-Perricaudet, L., and et al. (1992). In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. *Cell* 68, 143-155.
113. Sutter, G., and Moss, B. (1992). Nonreplicating vaccinia vector efficiently expresses recombinant genes. *Proc Natl Acad Sci U S A* 89, 10847-10851.
114. Walsh, C. E., Liu, J. M., Xiao, X., Young, N. S., Nienhuis, A. W., and Samulski, R. J. (1992). Regulated high level expression of a human gamma-globin gene introduced into erythroid cells by an adeno-associated virus vector. *Proc Natl Acad Sci U S A* 89, 7257-7261.
115. Rosenfeld, M. A., Siegfried, W., Yoshimura, K., Yoneyama, K., Fukayama, M., Stier, L. E., Paakko, P. K., Gilardi, P., Stratford-Perricaudet, L. D., Perricaudet, M., and et al. (1991). Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. *Science* 252, 431-434.
116. Taketo, M., Schroeder, A. C., Mobraaten, L. E., Gunning, K. B., Hanten, G., Fox, R. R., Roderick, T. H., Stewart, C. L., Lilly, F., Hansen, C. T., and et al. (1991). FVB/N: an inbred mouse strain preferable for transgenic analyses. *Proc Natl Acad Sci U S A* 88, 2065-2069.

117. Wang, Q., Konan, V., and Taylor, M. W. (1991). Expression of the APRT gene in an adenovirus vector system as a model for studying gene therapy. *Adv Exp Med Biol* 309B, 61-66.
118. Wu, G. Y., and Wu, C. H. (1991). Delivery systems for gene therapy. *Biotherapy* 3, 87-95.
119. Cooper, D. N., and Barondes, S. H. (1990). Evidence for export of a muscle lectin from cytosol to extracellular matrix and for a novel secretory mechanism. *J Cell Biol* 110, 1681-1691.
120. Geller, A. I., and Freese, A. (1990). Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of *Escherichia coli* beta-galactosidase. *Proc Natl Acad Sci U S A* 87, 1149-1153.
121. United States Patent No. 4,946,778 by Ladner et al, issued August 7, 1990. Single polypeptide chain binding molecules.
122. Stratford-Perricaudet, L. D., Levrero, M., Chasse, J. F., Perricaudet, M., and Briand, P. (1990). Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. *Hum Gene Ther* 1, 241-256.
123. Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., and Felgner, P. L. (1990). Direct gene transfer into mouse muscle in vivo. *Science* 247, 1465-1468.
124. Ausubel et al (1989). *Current Protocols in Molecular Biology*, Vol I (New York, NY, Green Publishing Associates, Inc. and John Wiley and Sons, Inc.) pp. 2.10.3.
125. Feichtinger, W., and Schmid, M. (1989). Increased frequencies of sister chromatid exchanges at common fragile sites (1)(q42) and (19)(q13). *Hum Genet* 83, 145-147.
126. WIPO, International Patent No. WO 89/12690 by Gargan et al. Issued December 12, 1989. International Application No. PCT/US89/02545. Method for the production of monoclonal antibodies utilizing a germfree animal.
127. Huse, W. D., Sastry, L., Iverson, S. A., Kang, A. S., Alting-Mees, M., Burton, D. R., Benkovic, S. J., and Lerner, R. A. (1989). Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. *Science* 246, 1275-1281.
128. Miller, A. D., and Rosman, G. J. (1989). Improved retroviral vectors for gene transfer and expression. *Biotechniques* 7, 980-990.
129. Barondes, S. H., Gitt, M. A., Leffler, H., and Cooper, D. N. (1988). Multiple soluble vertebrate galactoside-binding lectins. *Biochimie* 70, 1627-1632.

130. Hambor, J. E., Hauer, C. A., Shu, H. K., Groger, R. K., Kaplan, D. R., and Tykocinski, M. L. (1988). Use of an Epstein-Barr virus episomal replicon for anti-sense RNA-mediated gene inhibition in a human cytotoxic T-cell clone. *Proc Natl Acad Sci U S A* 85, 4010-4014.
131. Haseloff, J., and Gerlach, W. L. (1988). Simple RNA enzymes with new and highly specific endoribonuclease activities. *Nature* 334, 585-591.
132. Nicolau, C., Legrand, A., and Grosse, E. (1987). Liposomes as carriers for in vivo gene transfer and expression. *Methods Enzymol* 149, 157-176.
133. Been, M. D., and Cech, T. R. (1986). One binding site determines sequence specificity of Tetrahymena pre-rRNA self-splicing, trans-splicing, and RNA enzyme activity. *Cell* 47, 207-216.
134. Zaug, A. J., Been, M. D., and Cech, T. R. (1986). The Tetrahymena ribozyme acts like an RNA restriction endonuclease. *Nature* 324, 429-433.
135. Zaug, A. J., and Cech, T. R. (1986). The intervening sequence RNA of Tetrahymena is an enzyme. *Science* 231, 470-475.
136. Cole, S. P. C., Kozbor, D., and Roder, J. C. (1985). Strategies for production of human monoclonal antibodies. In *Hybridoma Technology in the Biosciences and Medicine*, T. A. Springer, ed. (New York, N.Y., Plenum Press,), pp. 43-55.
137. Takeda, S., Naito, T., Hama, K., Noma, T., and Honjo, T. (1985). Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences. *Nature* 314, 452-454.
138. Morrison, S. L., Johnson, M. J., Herzenberg, L. A., and Oi, V. T. (1984). Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. *Proc Natl Acad Sci U S A* 81, 6851-6855.
139. Neuberger, M. S., Williams, G. T., and Fox, R. O. (1984). Recombinant antibodies possessing novel effector functions. *Nature* 312, 604-608.
140. Zaug, A. J., Kent, J. R., and Cech, T. R. (1984). A labile phosphodiester bond at the ligation junction in a circular intervening sequence RNA. *Science* 224, 574-578.
141. Cote, R. J., Morrissey, D. M., Houghton, A. N., Beattie, E. J., Jr., Oettgen, H. F., and Old, L. J. (1983). Generation of human monoclonal antibodies reactive with cellular antigens. *Proc Natl Acad Sci U S A* 80, 2026-2030.
142. Kozbor, D., and Roder, J. C. (1983). The production of monoclonal antibodies from human lymphocytes. *Immunology Today* 4, 72-79.

143. Cifone, M. A., and Fidler, I. J. (1980). Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma. Proc Natl Acad Sci U S A 77, 1039-1043.

144. Kohler, G., and Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497.


The referenced citations are listed in the accompanying PTO Form 1449 and copies of the references are provided.

Identification of the above-listed references is not to be construed as an admission of the Applicants or the attorneys of the Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the above-mentioned application.

Please charge our Deposit Account No. 02-4377 if there is any additional fee required. Two copies of this communication are enclosed.

Respectfully submitted,
BAKER BOTTS L.L.P.




Lisa B. Koe,
Patent Office Reg. No. 35,225

BAKER BOTTS L.L.P.
30 Rockefeller Plaza
New York, NY 10112-4498
(212) 408-2628

Attorney for Applicants

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A34694-A-PCT-USA-A (070050.2544)		Serial No. 10/795,927
	Applicant Fisher et al.		
	Filing Date March 8, 2004	Group 1614	
	Examiner tba		



U.S. PATENT DOCUMENTS

*Exam. Init.		Document No.							Date	Name	Class	Subclass	Filing Date if Appro.
		1.	6	2	5	5	0	7	1	07/03/01	Beach et al.		
		2.	6	2	5	5	0	4	9	07/03/01	Fisher		
		3.	6	1	8	4	0	3	2	02/06/01	Fisher		
		10.	6	0	2	5	1	9	2	02/15/00	Beach et al.		
		12.	6	1	5	9	7	5	1	12/12/00	Fisher		
		42.	5	8	5	1	7	6	4	12/22/98	Fisher et al.		
		107.	5	0	9	3	2	4	6	03/03/92	Cech et al.		
		121.	4	9	4	6	7	7	8	08/07/90	Ladner et al.		

FOREIGN PATENT DOCUMENTS

			Document No.	Date	Country	Class	Subclass	<u>Translation</u> Yes No
	/		22.	WO 99/49898	10/07/99	WIPO		
	/		69.	WO 96/21671	07/18/96	WIPO		
	/		108.	WO 92/08131	05/14/92	WIPO		
	/		126.	WO 89/12690	12/12/89	WIPO		

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

NY02:498062.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34694-A-PCT-USA-A (070050.2544)	Serial No. 10/795,927
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher et al.	
	Filing Date March 8, 2004	Group 1614
	Examiner tba	

	4.	Hotta, K., Funahashi, T., Matsukawa, Y., Takahashi, M., Nishizawa, H., Kishida, K., Matsuda, M., Kuriyama, H., Kihara, S., Nakamura, T., <i>et al.</i> (2001). Galectin-12, an Adipose-expressed Galectin-like Molecule Possessing Apoptosis-inducing Activity. <i>J Biol Chem</i> 276, 34089-34097.
	5.	Peng, X. Y., Won, J. H., Rutherford, T., Fujii, T., Zeltermann, D., Pizzorno, G., Sapi, E., Leavitt, J., Kacinski, B., Crystal, R., <i>et al.</i> (2001). The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. <i>Cancer Res</i> 61, 4405-4413.
	6.	Perrais, M., Pigny, P., Ducourouble, M. P., Petitprez, D., Porchet, N., Aubert, J. P., and Van Seuningen, I. (2001). Characterization of human mucin gene MUC4 promoter: importance of growth factors and proinflammatory cytokines for its regulation in pancreatic cancer cells. <i>J Biol Chem</i> 276, 30923-30933..
	7.	Tanaka, M., Inase, N., Miyake, S., and Yoshizawa, Y. (2001). Neuron specific enolase promoter for suicide gene therapy in small cell lung carcinoma. <i>Anticancer Res</i> 21, 291-294..
	8.	Xie, X., Zhao, X., Liu, Y., Young, C. Y., Tindall, D. J., Slawin, K. M., and Spencer, D. M. (2001). Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter. <i>Hum Gene Ther</i> 12, 549-561.
	9.	Adachi, Y., Reynolds, P. N., Yamamoto, M., Grizzle, W. E., Overturf, K., Matsubara, S., Muramatsu, T., and Curiel, D. T. (2000). Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors. <i>Cancer Res</i> 60, 4305-4310
	11.	Curran, M. A., Kaiser, S. M., Achacoso, P. L., and Nolan, G. P. (2000). Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. <i>Mol Ther</i> 1, 31-38.
	13.	Gopalkrishnan, R. V., Roberts, T., Tuli, S., Kang, D., Christiansen, K. A., and Fisher, P. B. (2000). Molecular characterization of prostate carcinoma tumor antigen-1, PCTA-1, a human galectin-8 related gene. <i>Oncogene</i> 19, 4405-4416.

NY02:498062.1

Examiner

Date Considered

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34694-A-PCT-USA-A (070050.2544)	Serial No. 10/795,927
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher et al.	
	Filing Date March 8, 2004	Group 1614
	Examiner tba	

14.	Inase, N., Horita, K., Tanaka, M., Miyake, S., Ichioka, M., and Yoshizawa, Y. (2000). Use of gastrin-releasing peptide promoter for specific expression of thymidine kinase gene in small-cell lung carcinoma cells. <i>Int J Cancer</i> 85, 716-719..
15.	O'Keefe, D. S., Uchida, A., Bacich, D. J., Watt, F. B., Martorana, A., Molloy, P. L., and Heston, W. D. (2000). Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. <i>Prostate</i> 45, 149-157..
16.	Van Seuningen, et al. (2000). Homo sapiens mucin (MUC4) gene, promoter sequence and partial cds. GenBank Accession No. AF241535..
17.	Bassen, R., Brichory, F., Caulet-Maugendre, S., Bidon, N., Delaval, P., Desrues, B., and Dazord, L. (1999). Expression of Po66-CBP, a type-8 galectin, in different healthy, tumoral and peritumoral tissues. <i>Anticancer Res</i> 19, 5429-5433.
18.	Case, S. S., Price, M. A., Jordan, C. T., Yu, X. J., Wang, L., Bauer, G., Haas, D. L., Xu, D., Stripecke, R., Naldini, L., <i>et al.</i> (1999). Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. <i>Proc Natl Acad Sci U S A</i> 96, 2988-2993.
19.	Connelly, S. (1999). Adenoviral vectors for liver-directed gene therapy. <i>Curr Opin Mol Ther</i> 1, 565-572
20.	Cooper, D. N., and Barondes, S. H. (1999). God must love galectins; he made so many of them. <i>Glycobiology</i> 9, 979-984.
21.	Ellerhorst, J., Nguyen, T., Cooper, D. N., Lotan, D., and Lotan, R. (1999). Differential expression of endogenous galectin-1 and galectin-3 in human prostate cancer cell lines and effects of overexpressing galectin-1 on cell phenotype. <i>Int J Oncol</i> 14, 217-224.
23.	Gopalkrishnan, R. V., Christiansen, K. A., Goldstein, N. I., DePinho, R. A., and Fisher, P. B. (1999). Use of the human EF-1alpha promoter for expression can significantly increase success in establishing stable cell lines with consistent expression: a study using the tetracycline-inducible system in human cancer cells. <i>Nucleic Acids Res</i> 27, 4775-4782.

NY02:498062.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34694-A-PCT-USA-A (070050.2544)	Serial No. 10/795,927
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher et al.	
	Filing Date March 8, 2004	Group 1614
	Examiner tba	

		24.	Greenhalgh, C. J., Beckham, S. A., and Newton, S. E. (1999). Galectins from sheep gastrointestinal nematode parasites are highly conserved. <i>Mol Biochem Parasitol</i> 98, 285-289.
		25.	Hsu, D. K., Dowling, C. A., Jeng, K. C., Chen, J. T., Yang, R. Y., and Liu, F. T. (1999). Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. <i>Int J Cancer</i> 81, 519-526.
		26.	Katabi, M. M., Chan, H. L., Karp, S. E., and Batist, G. (1999). Hexokinase type II: a novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells. <i>Hum Gene Ther</i> 10, 155-164.
		27.	Lu, Y., and Lotan, R. (1999). Transcriptional regulation by butyrate of mouse galectin-1 gene in embryonal carcinoma cells. <i>Biochim Biophys Acta</i> 1444, 85-91.
		28.	Maldonado, C. A., Castagna, L. F., Rabinovich, G. A., and Landa, C. A. (1999). Immunocytochemical Study of the Distribution of a 16-kDa Galectin in the Chicken Retina. <i>Invest Ophthalmol Vis Sci</i> 40, 2971-2977.
		29.	Pan, C. X., and Koeneman, K. S. (1999). A novel tumor-specific gene therapy for bladder cancer. <i>Med Hypotheses</i> 53, 130-135.
		30.	Polo, J. M., Belli, B. A., Driver, D. A., Frolov, I., Sherrill, S., Hariharan, M. J., Townsend, K., Perri, S., Mento, S. J., Jolly, D. J., <i>et al.</i> (1999). Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. <i>Proc Natl Acad Sci U S A</i> 96, 4598-4603.
		31.	Puch, S., and Bhavanandan, V. P. (1999). Endogenous carbohydrate-binding proteins of rabbit and human bladder. <i>Urology</i> 53, 848-852.
		32.	Rommelink, M., Darro, F., Decaestecker, C., De Decker, R., Bovin, N. V., Gebhart, M., Kaltner, H., Gabius, H. J., Kiss, R., Salmon, I., and Danguy, A. (1999). In vitro influence of lectins and neoglycoconjugates on the growth of three human sarcoma cell lines. <i>J Cancer Res Clin Oncol</i> 125, 275-285.

NY02:498062.1

Examiner

Date Considered

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34694-A-PCT-USA-A (070050.2544)	Serial No. 10/795,927
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher et al.	
	Filing Date March 8, 2004	Group 1614
	Examiner tba	

	33.	Stackhouse, M. A., Buchsbaum, D. J., Kancharla, S. R., Grizzle, W. E., Grimes, C., Laffoon, K., Pederson, L. C., and Curiel, D. T. (1999). Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors. <i>Cancer Gene Ther</i> 6, 209-219.
	34.	Willis, A. E. (1999). Translational control of growth factor and proto-oncogene expression. <i>Int J Biochem Cell Biol</i> 31, 73-86.
	35.	Zhang, W. W. (1999). Development and application of adenoviral vectors for gene therapy of cancer. <i>Cancer Gene Ther</i> 6, 113-138.
	36.	Berthon, P., Valeri, A., Cohen-Akenine, A., Drelon, E., Paiss, T., Wohr, G., Latil, A., Millasseau, P., Mellah, I., Cohen, N., <i>et al.</i> (1998). Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. <i>Am J Hum Genet</i> 62, 1416-1424.
	37.	Blaser, C., Kaufmann, M., Muller, C., Zimmermann, C., Wells, V., Mallucci, L., and Pircher, H. (1998). Beta-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. <i>Eur J Immunol</i> 28, 2311-2319.
	38.	Brichory, et al. (1998). Homo sapiens Po66 carbohydrate binding protein mRNA, complete cds. GenBank Accession No. AF074000.
	39.	Brichory, et al. (1998). Homo sapiens Po66 carbohydrate binding protein 1 mRNA, complete cds. GenBank Accession No. AF074001.
	40.	Brichory, et al. (1998). Homo sapiens Po66 carbohydrate binding protein 2 mRNA, complete cds. GenBank Accession No. AF074002.
	41.	Cortegano, I., del Pozo, V., Cardaba, B., de Andres, B., Gallardo, S., del Amo, A., Arrieta, I., Jurado, A., Palomino, P., Liu, F. T., and Lahoz, C. (1998). Galectin-3 down-regulates IL-5 gene expression on different cell types. <i>J Immunol</i> 161, 385-389.

NY02:498062.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A34694-A-PCT-USA-A (070050.2544)	Serial No. 10/795,927
	Applicant Fisher et al.	
	Filing Date March 8, 2004	Group 1614
	Examiner tba	

43.	Gitt, M. A., Colnot, C., Poirier, F., Nani, K. J., Barondes, S. H., and Leffler, H. (1998a). Galectin-4 and galectin-6 are two closely related lectins expressed in mouse gastrointestinal tract. <i>J Biol Chem</i> 273, 2954-2960.
44.	Gitt, M. A., Xia, Y. R., Atchison, R. E., Lusic, A. J., Barondes, S. H., and Leffler, H. (1998). Sequence, structure, and chromosomal mapping of the mouse <i>Lgals6</i> gene, encoding galectin-6. <i>J Biol Chem</i> 273, 2961-2970.
45.	Iglesias, M. M., Rabinovich, G. A., Ambrosio, A. L., Castagna, L. F., Sotomayor, C. E., and Wolfenstein-Todel, C. (1998). Purification of galectin-3 from ovine placenta: developmentally regulated expression and immunological relevance. <i>Glycobiology</i> 8, 59-65.
46.	Kaltner, H., and Stierstorfer, B. (1998). Animal lectins as cell adhesion molecules. <i>Acta Anat (Basel)</i> 161, 162-179.
47.	Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML, Matusik RJ. (1998). Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. <i>Lab Invest.</i> 1998 78(3):319-333
48.	Lu, Y., Amos, B., Cruise, E., Lotan, D., and Lotan, R. (1998). A parallel association between differentiation and induction of galectin-1, and inhibition of galectin-3 by retinoic acid in mouse embryonal carcinoma F9 cells. <i>Biol Chem</i> 379, 1323-1331.
49.	Olsen, J. C. (1998). Gene transfer vectors derived from equine infectious anemia virus. <i>Gene Ther</i> 5, 1481-1487.
50.	Sarafian, V., Jadot, M., Foidart, J. M., Letesson, J. J., Van den Brule, F., Castronovo, V., Wattiaux, R., and Coninck, S. W. (1998). Expression of Lamp-1 and Lamp-2 and their interactions with galectin-3 in human tumor cells. <i>Int J Cancer</i> 75, 105-111.

NY02:498062.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34694-A-PCT-USA-A (070050.2544)	Serial No. 10/795,927
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher et al.	
	Filing Date March 8, 2004	Group 1614
	Examiner tba	

	51.	Su, Z. Z., Madireddi, M. T., Lin, J. J., Young, C. S., Kitada, S., Reed, J. C., Goldstein, N. I., and Fisher, P. B. (1998). The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. <i>Proc Natl Acad Sci U S A</i> 95, 14400-14405.
	52.	Vyakarnam, A., Lenneman, A. J., Lakkides, K. M., Patterson, R. J., and Wang, J. L. (1998). A comparative nuclear localization study of galectin-1 with other splicing components. <i>Exp Cell Res</i> 242, 419-428.
	53.	Akahani, S., Nangia-Makker, P., Inohara, H., Kim, H. R., and Raz, A. (1997). Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. <i>Cancer Res</i> 57, 5272-5276.
	54.	Arata, Y., Hirabayashi, J., and Kasai, K. (1997). The two lectin domains of the tandem-repeat 32-kDa galectin of the nematode <i>Caenorhabditis elegans</i> have different binding properties. Studies with recombinant protein. <i>J Biochem (Tokyo)</i> 121, 1002-1009.
	55.	Bresalier, R. S., Yan, P. S., Byrd, J. C., Lotan, R., and Raz, A. (1997). Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. <i>Cancer</i> 80, 776-787.
	56.	Chadli, A., LeCaer, J. P., Bladier, D., Joubert-Caron, R., and Caron, M. (1997). Purification and characterization of a human brain galectin-1 ligand. <i>J Neurochem</i> 68, 1640-1647.
	57.	Cooper, D. N., Boulianne, R. P., Charlton, S., Farrell, E. M., Sucher, A., and Lu, B. C. (1997). Fungal galectins, sequence and specificity of two isolectins from <i>Coprinus cinereus</i> . <i>J Biol Chem</i> 272, 1514-1521.
	58.	Hughes, R. C. (1997). The galectin family of mammalian carbohydrate-binding molecules. <i>Biochem Soc Trans</i> 25, 1194-1198.
	59.	Lutowski, D., Fouillit, M., Bourin, P., Mellottee, D., Denize, N., Pontet, M., Bladier, D., Caron, M., and Joubert-Caron, R. (1997). Externalization and binding of galectin-1 on cell surface of K562 cells upon erythroid differentiation. <i>Glycobiology</i> 7, 1193-1199.

NY02:498062.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34694-A-PCT-USA-A (070050.2544)	Serial No. 10/795,927
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher et al.	
	Filing Date March 8, 2004	Group 1614
	Examiner tba	

	60.	Maquoi, E., van den Brule, F. A., Castronovo, V., and Foidart, J. M. (1997). Changes in the distribution pattern of galectin-1 and galectin-3 in human placenta correlates with the differentiation pathways of trophoblasts. <i>Placenta</i> 18, 433-439.
	61.	Mehul, B., and Hughes, R. C. (1997). Plasma membrane targetting, vesicular budding and release of galectin 3 from the cytoplasm of mammalian cells during secretion. <i>J Cell Sci</i> 110 (Pt 10), 1169-1178.
	62.	Takakuwa, K., Fujita, K., Kikuchi, A., Sugaya, S., Yahata, T., Aida, H., Kurabayashi, T., Hasegawa, I., and Tanaka, K. (1997). Direct intratumoral gene transfer of the herpes simplex virus thymidine kinase gene with DNA-liposome complexes: growth inhibition of tumors and lack of localization in normal tissues. <i>Jpn J Cancer Res</i> 88, 166-175.
	63.	Vyakarnam, A., Dagher, S. F., Wang, J. L., and Patterson, R. J. (1997). Evidence for a role for galectin-1 in pre-mRNA splicing. <i>Mol Cell Biol</i> 17, 4730-4737.
	64.	Wada, J., and Kanwar, Y. S. (1997). Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. <i>J Biol Chem</i> 272, 6078-6086.
	65.	Boyce, F. M., and Bucher, N. L. (1996). Baculovirus-mediated gene transfer into mammalian cells. <i>Proc Natl Acad Sci U S A</i> 93, 2348-2352.
	66.	Bresalier, R. S., Byrd, J. C., Wang, L., and Raz, A. (1996). Colon cancer mucin: a new ligand for the beta-galactoside-binding protein galectin-3. <i>Cancer Res</i> 56, 4354-4357.
	67.	Chammas, R., Jasiulionis, M. G., Ventura, A. M., Travassos, L. R., and Brentani, R. R. (1996). Laminin-binding proteins in EJ-ras-transformed fibroblasts. <i>Braz J Med Biol Res</i> 29, 1141-1149.
	68.	Colnot, C., Ripoche, M. A., Scaerou, F., Foulis, D., and Poirier, F. (1996). Galectins in mouse embryogenesis. <i>Biochem Soc Trans</i> 24, 141-146.
	70.	Gillenwater, A., Xu, X. C., el-Naggar, A. K., Clayman, G. L., and Lotan, R. (1996). Expression of galectins in head and neck squamous cell carcinoma. <i>Head Neck</i> 18, 422-432.

NY02:498062.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34694-A-PCT-USA-A (070050.2544)	Serial No. 10/795,927
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher et al.	
	Filing Date March 8, 2004	Group 1614
	Examiner tba	

	71.	Gingrich, J. R., Barrios, R. J., Morton, R. A., Boyce, B. F., DeMayo, F. J., Finegold, M. J., Angelopoulou, R., Rosen, J. M., and Greenberg, N. M. (1996). Metastatic prostate cancer in a transgenic mouse. <i>Cancer Res</i> 56, 4096-4102.
	72.	Gopalkrishnan, R. V., Dolle, P., Mattei, M. G., La Thangue, N. B., and Kedinger, C. (1996). Genomic structure and developmental expression of the mouse cell cycle regulatory transcription factor DP1. <i>Oncogene</i> 13, 2671-2680.
	73.	Hadj Sahraoui, Y., Sève, A.-P., Doyennette-Moyne, M.-A., Saffar, L., Felin, M., Aubery, M., Gattegno, L., and Hubert, J. (1996). Nuclear and cytoplasmic expressions of the carbohydrate-binding protein CBP70 in tumoral or healthy cells of the macrophagic lineage. <i>J Cell Biochem</i> 62, 529-542.
	74.	Hebert, E., Roche, A. C., Nachtigal, M., and Monsigny, M. (1996). Transformation but not ras-transfection increases the expression of galectin-3 in human HOS cells. <i>C R Acad Sci III</i> 319, 871-877.
	75.	Jiang, H., Su, Z. Z., Lin, J. J., Goldstein, N. I., Young, C. S., and Fisher, P. B. (1996). The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. <i>Proc Natl Acad Sci U S A</i> 93, 9160-9165.
	76.	Kasai, K., and Hirabayashi, J. (1996). Galectins: a family of animal lectins that decipher glycocodes. <i>J Biochem (Tokyo)</i> 119, 1-8
	77.	Lan, K. H., Kanai, F., Shiratori, Y., Okabe, S., Yoshida, Y., Wakimoto, H., Hamada, H., Tanaka, T., Ohashi, M., and Omata, M. (1996). Tumor-specific gene expression in carcinoembryonic antigen-producing gastric cancer cells using adenovirus vectors. <i>Gastroenterology</i> 111, 1241-1251.
	78.	Strayer, D. S., and Milano, J. (1996). SV40 mediates stable gene transfer in vivo. <i>Gene Ther</i> 3, 581-587.

NY02:498062.1

Examiner

Date Considered

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34694-A-PCT-USA-A (070050.2544)	Serial No. 10/795,927
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher et al.	
	Filing Date March 8, 2004	Group 1614
	Examiner tba	

	79.	Su, Z. Z., Lin, J., Shen, R., Fisher, P. E., Goldstein, N. I., and Fisher, P. B. (1996). Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family. <i>Proc Natl Acad Sci U S A</i> 93, 7252-7257.
	80.	Su, Z. Z. et al. (1996). Human prostate carcinoma tumor antigen (pcta-1) mRNA, complete cds. GenBank Accession No L78132.
	81.	Wagner-Hulsmann, C., Bachinski, N., Diehl-Seifert, B., Blumbach, B., Steffen, R., Pancer, Z., and Muller, W. E. (1996). A galectin links the aggregation factor to cells in the sponge (<i>Geodia cydonium</i>) system. <i>Glycobiology</i> 6, 785-793.
	82.	Yang, R. Y., Hsu, D. K., and Liu, F. T. (1996). Expression of galectin-3 modulates T-cell growth and apoptosis. <i>Proc Natl Acad Sci U S A</i> 93, 6737-6742.
	83.	Cho, M., and Cummings, R. D. (1995a). Galectin-1, a beta-galactoside-binding lectin in Chinese hamster ovary cells. II. Localization and biosynthesis. <i>J Biol Chem</i> 270, 5207-5212.
	84.	Cho, M., and Cummings, R. D. (1995b). Galectin-1, a beta-galactoside-binding lectin in Chinese hamster ovary cells. I. Physical and chemical characterization. <i>J Biol Chem</i> 270, 5198-5206.
	85.	Dagher, S. F., Wang, J. L., and Patterson, R. J. (1995). Identification of galectin-3 as a factor in pre-mRNA splicing. <i>Proc Natl Acad Sci U S A</i> 92, 1213-1217.
	86.	Gitt, M. A., Wiser, M. F., Leffler, H., Herrmann, J., Xia, Y. R., Massa, S. M., Cooper, D. N., Lusi, A. J., and Barondes, S. H. (1995). Sequence and mapping of galectin-5, a beta-galactoside-binding lectin, found in rat erythrocytes. <i>J Biol Chem</i> 270, 5032-5038.
	87.	Greenberg, N. M., DeMayo, F., Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., Cunha, G. R., Donjacour, A. A., Matusik, R. J., and Rosen, J. M. (1995). Prostate cancer in a transgenic mouse. <i>Proc Natl Acad Sci U S A</i> 92, 3439-3443.

NY02:498062.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34694-A-PCT-USA-A (070050.2544)	Serial No. 10/795,927
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher et al.	
	Filing Date March 8, 2004	Group 1614
	Examiner tba	

	88.	Hadari, Y. R., Paz, K., Dekel, R., Mestrovic, T., Accili, D., and Zick, Y. (1995). Galectin-8. A new rat lectin, related to galectin-4. <i>J Biol Chem</i> 270, 3447-3453.
	89.	Ido, A., Nakata, K., Kato, Y., Nakao, K., Murata, K., Fujita, M., Ishii, N., Tamaoki, T., Shiku, H., and Nagataki, S. (1995). Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. <i>Cancer Res</i> 55, 3105-3109.
	90.	Inohara, H., and Raz, A. (1995). Functional evidence that cell surface galectin-3 mediates homotypic cell adhesion. <i>Cancer Res</i> 55, 3267-3271.
	91.	Li, Y. S., Ramsay, D. A., Fan, Y. S., Armstrong, R. F., and Del Maestro, R. F. (1995). Cytogenetic evidence that a tumor suppressor gene in the long arm of chromosome 1 contributes to glioma growth. <i>Cancer Genet Cytogenet</i> 84, 46-50.
	92.	Perillo, N. L., Pace, K. E., Seilhamer, J. J., and Baum, L. G. (1995). Apoptosis of T cells mediated by galectin-1. <i>Nature</i> 378, 736-739.
	93.	Rini, J. M. (1995). X-ray crystal structures of animal lectins. <i>Curr Opin Struct Biol</i> 5, 617-621.
	94.	Schoeppner, H. L., Raz, A., Ho, S. B., and Bresalier, R. S. (1995). Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. <i>Cancer</i> 75, 2818-2826.
	95.	Barondes, S. H., Castronovo, V., Cooper, D. N., Cummings, R. D., Drickamer, K., Feizi, T., Gitt, M. A., Hirabayashi, J., Hughes, C., Kasai, K., and et al. (1994). Galectins: a family of animal beta-galactoside-binding lectins. <i>Cell</i> 76, 597-598.
	96.	Barondes, S. H., Cooper, D. N., Gitt, M. A., and Leffler, H. (1994). Galectins. Structure and function of a large family of animal lectins. <i>J Biol Chem</i> 269, 20807-20810.

NY02:498062.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A34694-A-PCT-USA-A (070050.2544)	Serial No. 10/795,927
	Applicant Fisher et al.	
	Filing Date March 8, 2004	Group 1614
	Examiner tba	

97.	Bett, A. J., Haddara, W., Prevec, L., and Graham, F. L. (1994). An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. <i>Proc Natl Acad Sci U S A</i> 91, 8802-8806.
98.	Hayashi, Y., DePaoli, A. M., Burant, C. F., and Refetoff, S. (1994). Expression of a thyroid hormone-responsive recombinant gene introduced into adult mice livers by replication-defective adenovirus can be regulated by endogenous thyroid hormone receptor. <i>J Biol Chem</i> 269, 23872-23875.
99.	Lotan, R., Belloni, P. N., Tressler, R. J., Lotan, D., Xu, X. C., and Nicolson, G. L. (1994). Expression of galectins on microvessel endothelial cells and their involvement in tumour cell adhesion. <i>Glycoconj J</i> 11, 462-468
100.	Murty, V. V., Li, R. G., Mathew, S., Reuter, V. E., Bronson, D. L., Bosl, G. J., and Chaganti, R. S. (1994). Replication error-type genetic instability at 1q42-43 in human male germ cell tumors. <i>Cancer Res</i> 54, 3983-3985.
101.	Rossi, J. J. (1994). Practical ribozymes. Making ribozymes work in cells. <i>Curr Biol</i> 4, 469-471.
102.	Shen, R., Su, Z. Z., Olsson, C. A., Goldstein, N. I., and Fisher, P. B. (1994). Surface-epitope masking: a strategy for the development of monoclonal antibodies specific for molecules expressed on the cell surface. <i>J Natl Cancer Inst</i> 86, 91-98.
103.	Welch, D. R., Chen, P., Miele, M. E., McGary, C. T., Bower, J. M., Stanbridge, E. J., and Weissman, B. E. (1994). Microcell-mediated transfer of chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorigenicity. <i>Oncogene</i> 9, 255-262.
104.	Li, Q., Kay, M. A., Finegold, M., Stratford-Perricaudet, L. D., and Woo, S. L. (1993). Assessment of recombinant adenoviral vectors for hepatic gene therapy. <i>Hum Gene Ther</i> 4, 403-409.

NY02:498062.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A34694-A-PCT-USA-A (070050.2544)	Serial No. 10/795,927
	Applicant Fisher et al.	
	Filing Date March 8, 2004	Group 1614
	Examiner tba	

105.	Mastrangeli, A., Danel, C., Rosenfeld, M. A., Stratford-Perricaudet, L., Perricaudet, M., Pavirani, A., Lecocq, J. P., and Crystal, R. G. (1993). Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer. <i>J Clin Invest</i> 91, 225-234.
106.	Ragot, T., Vincent, N., Chafey, P., Vigne, E., Gilgenkrantz, H., Couton, D., Cartaud, J., Briand, P., Kaplan, J. C., Perricaudet, M., and et al. (1993). Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. <i>Nature</i> 361, 647-650.
109.	Jaffe, H. A., Danel, C., Longenecker, G., Metzger, M., Setoguchi, Y., Rosenfeld, M. A., Gant, T. W., Thorgerisson, S. S., Stratford-Perricaudet, L. D., Perricaudet, M., and et al. (1992). Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. <i>Nat Genet</i> 1, 372-378.
110.	Legendre, J. Y., and Szoka, F. C., Jr. (1992). Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: comparison with cationic liposomes. <i>Pharm Res</i> 9, 1235-1242.
111.	Quantin, B., Perricaudet, L. D., Tajbakhsh, S., and Mandel, J. L. (1992). Adenovirus as an expression vector in muscle cells in vivo. <i>Proc Natl Acad Sci U S A</i> 89, 2581-2584.
112.	Rosenfeld, M. A., Yoshimura, K., Trapnell, B. C., Yoneyama, K., Rosenthal, E. R., Dalemans, W., Fukayama, M., Bargon, J., Stier, L. E., Stratford-Perricaudet, L., and et al. (1992). In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. <i>Cell</i> 68, 143-155.
113.	Sutter, G., and Moss, B. (1992). Nonreplicating vaccinia vector efficiently expresses recombinant genes. <i>Proc Natl Acad Sci U S A</i> 89, 10847-10851.

NY02:498062.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34694-A-PCT-USA-A (070050.2544)	Serial No. 10/795,927
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher et al.	
	Filing Date March 8, 2004	Group 1614
	Examiner tba	

	114.	Walsh, C. E., Liu, J. M., Xiao, X., Young, N. S., Nienhuis, A. W., and Samulski, R. J. (1992). Regulated high level expression of a human gamma-globin gene introduced into erythroid cells by an adeno-associated virus vector. <i>Proc Natl Acad Sci U S A</i> 89, 7257-7261.
	115.	Rosenfeld, M. A., Siegfried, W., Yoshimura, K., Yoneyama, K., Fukayama, M., Stier, L. E., Paakko, P. K., Gilardi, P., Stratford-Perricaudet, L. D., Perricaudet, M., and et al. (1991). Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. <i>Science</i> 252, 431-434.
	116.	Taketo, M., Schroeder, A. C., Mobraaten, L. E., Gunning, K. B., Hanten, G., Fox, R. R., Roderick, T. H., Stewart, C. L., Lilly, F., Hansen, C. T., and et al. (1991). FVB/N: an inbred mouse strain preferable for transgenic analyses. <i>Proc Natl Acad Sci U S A</i> 88, 2065-2069.
	117.	Wang, Q., Konan, V., and Taylor, M. W. (1991). Expression of the APRT gene in an adenovirus vector system as a model for studying gene therapy. <i>Adv Exp Med Biol</i> 309B, 61-66.
	118.	Wu, G. Y., and Wu, C. H. (1991). Delivery systems for gene therapy. <i>Biotherapy</i> 3, 87-95.
	119.	Cooper, D. N., and Barondes, S. H. (1990). Evidence for export of a muscle lectin from cytosol to extracellular matrix and for a novel secretory mechanism. <i>J Cell Biol</i> 110, 1681-1691.
	120.	Geller, A. I., and Freese, A. (1990). Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of Escherichia coli beta-galactosidase. <i>Proc Natl Acad Sci U S A</i> 87, 1149-1153.
	122.	Stratford-Perricaudet, L. D., Levrero, M., Chasse, J. F., Perricaudet, M., and Briand, P. (1990). Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. <i>Hum Gene Ther</i> 1, 241-256.

NY02:498062.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A34694-A-PCT-USA-A (070050.2544)	Serial No. 10/795,927
	Applicant Fisher et al.	
	Filing Date March 8, 2004	Group 1614
	Examiner tba	

123.	Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., and Felgner, P. L. (1990). Direct gene transfer into mouse muscle in vivo. <i>Science</i> 247, 1465-1468.
124.	Ausubel et al (1989). <i>Current Protocols in Molecular Biology</i> , Vol I (New York, NY, Green Publishing Associates, Inc. and John Wiley and Sons, Inc.) pp. 2.10.3.
125.	Feichtinger, W., and Schmid, M. (1989). Increased frequencies of sister chromatid exchanges at common fragile sites (1)(q42) and (19)(q13). <i>Hum Genet</i> 83, 145-147.
127.	Huse, W. D., Sastry, L., Iverson, S. A., Kang, A. S., Alting-Mees, M., Burton, D. R., Benkovic, S. J., and Lerner, R. A. (1989). Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. <i>Science</i> 246, 1275-1281.
128.	Miller, A. D., and Rosman, G. J. (1989). Improved retroviral vectors for gene transfer and expression. <i>Biotechniques</i> 7, 980-990.
129.	Barondes, S. H., Gitt, M. A., Leffler, H., and Cooper, D. N. (1988). Multiple soluble vertebrate galactoside-binding lectins. <i>Biochimie</i> 70, 1627-1632.
130.	Hambor, J. E., Hauer, C. A., Shu, H. K., Groger, R. K., Kaplan, D. R., and Tykocinski, M. L. (1988). Use of an Epstein-Barr virus episomal replicon for anti-sense RNA-mediated gene inhibition in a human cytotoxic T-cell clone. <i>Proc Natl Acad Sci U S A</i> 85, 4010-4014.
131.	Haseloff, J., and Gerlach, W. L. (1988). Simple RNA enzymes with new and highly specific endoribonuclease activities. <i>Nature</i> 334, 585-591.
132.	Nicolau, C., Legrand, A., and Grosse, E. (1987). Liposomes as carriers for in vivo gene transfer and expression. <i>Methods Enzymol</i> 149, 157-176.
133.	Been, M. D., and Cech, T. R. (1986). One binding site determines sequence specificity of Tetrahymena pre-rRNA self-splicing, trans-splicing, and RNA enzyme activity. <i>Cell</i> 47, 207-216.

NY02:498062.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34694-A-PCT-USA-A (070050.2544)	Serial No. 10/795,927
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher et al.	
	Filing Date March 8, 2004	Group 1614
	Examiner tba	

	134.	Zaug, A. J., Been, M. D., and Cech, T. R. (1986). The Tetrahymena ribozyme acts like an RNA restriction endonuclease. <i>Nature</i> 324, 429-433.
	135.	Zaug, A. J., and Cech, T. R. (1986). The intervening sequence RNA of Tetrahymena is an enzyme. <i>Science</i> 231, 470-475.
	136.	Cole, S. P. C., Kozbor, D., and Roder, J. C. (1985). Strategies for production of human monoclonal antibodies. In <i>Hybridoma Technology in the Biosciences and Medicine</i> , T. A. Springer, ed. (New York, N.Y., Plenum Press,), pp. 43-55.
	137.	Takeda, S., Naito, T., Hama, K., Noma, T., and Honjo, T. (1985). Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences. <i>Nature</i> 314, 452-454.
	138.	Morrison, S. L., Johnson, M. J., Herzenberg, L. A., and Oi, V. T. (1984). Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. <i>Proc Natl Acad Sci U S A</i> 81, 6851-6855.
	139.	Neuberger, M. S., Williams, G. T., and Fox, R. O. (1984). Recombinant antibodies possessing novel effector functions. <i>Nature</i> 312, 604-608.
	140.	Zaug, A. J., Kent, J. R., and Cech, T. R. (1984). A labile phosphodiester bond at the ligation junction in a circular intervening sequence RNA. <i>Science</i> 224, 574-578.
	141.	Cote, R. J., Morrissey, D. M., Houghton, A. N., Beattie, E. J., Jr., Oettgen, H. F., and Old, L. J. (1983). Generation of human monoclonal antibodies reactive with cellular antigens. <i>Proc Natl Acad Sci U S A</i> 80, 2026-2030.
	142.	Kozbor, D., and Roder, J. C. (1983). The production of monoclonal antibodies from human lymphocytes. <i>Immunology Today</i> 4, 72-79.
	143.	Cifone, M. A., and Fidler, I. J. (1980). Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma. <i>Proc Natl Acad Sci U S A</i> 77, 1039-1043

NY02:498062.1

Examiner

Date Considered

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A34694-A-PCT-USA-A (070050.2544)	Serial No. 10/795,927
	Applicant Fisher et al.	
	Filing Date March 8, 2004	Group 1614
	Examiner tba	

		144.	Kohler, G., and Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497.
--	--	------	--

NY02:498062.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.